A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

PHASE2CompletedINTERVENTIONAL
Enrollment

606

Participants

Timeline

Start Date

November 27, 2017

Primary Completion Date

March 26, 2020

Study Completion Date

March 26, 2020

Conditions
Respiratory Disorders
Interventions
BIOLOGICAL

NTHi Mcat investigational vaccine (GSK3277511A)

Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.

BIOLOGICAL

Placebo

Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.

Trial Locations (67)

1000

GSK Investigational Site, Brussels

3000

GSK Investigational Site, Leuven

3600

GSK Investigational Site, Genk

4000

GSK Investigational Site, Liège

8500

GSK Investigational Site, Kortrijk

9000

GSK Investigational Site, Ghent

13285

GSK Investigational Site, Marseille

16508

GSK Investigational Site, Erie

20122

GSK Investigational Site, Milan

20142

GSK Investigational Site, Milan

20900

GSK Investigational Site, Monza

22927

GSK Investigational Site, Großhansdorf

23225

GSK Investigational Site, Richmond

23552

GSK Investigational Site, Lübeck

24210

GSK Investigational Site, Abingdon

27103

GSK Investigational Site, Winston-Salem

28007

GSK Investigational Site, Madrid

28117

GSK Investigational Site, Mooresville

28207

GSK Investigational Site, Charlotte

28223

GSK Investigational Site, Pozuelo de Alarcón/Madrid

28500

GSK Investigational Site, Vic

29303

GSK Investigational Site, Spartanburg

29340

GSK Investigational Site, Gaffney

29379

GSK Investigational Site, Union

29464

GSK Investigational Site, Mt. Pleasant

29609

GSK Investigational Site, Brest

32205

GSK Investigational Site, Jacksonville

32216

GSK Investigational Site, Jacksonville

33765

GSK Investigational Site, Clearwater

34295

GSK Investigational Site, Montpellier

34376

GSK Investigational Site, Immenhausen

37024

GSK Investigational Site, Negrar

39120

GSK Investigational Site, Magdeburg

43100

GSK Investigational Site, Parma

43213

GSK Investigational Site, Columbus

44124

GSK Investigational Site, Cona (FE)

51503

GSK Investigational Site, Council Bluffs

59808

GSK Investigational Site, Missoula

60389

GSK Investigational Site, Frankfurt am Main

60596

GSK Investigational Site, Frankfurt am Main

67207

GSK Investigational Site, Wichita

85018

GSK Investigational Site, Phoenix

85020

GSK Investigational Site, Phoenix

85213

GSK Investigational Site, Mesa

92262

GSK Investigational Site, Palm Springs

94010

GSK Investigational Site, Créteil

97330

GSK Investigational Site, Corvallis

97504

GSK Investigational Site, Medford

98801

GSK Investigational Site, Wenatchee

07753

GSK Investigational Site, Neptune City

T6G 2G3

GSK Investigational Site, Edmonton

V5Z 1M9

GSK Investigational Site, Vancouver

B3K 6R8

GSK Investigational Site, Halifax

B2N 1L2

GSK Investigational Site, Truro

H3T1E2

GSK Investigational Site, Montreal

G1V 4G5

GSK Investigational Site, Québec

J6E 2B4

GSK Investigational Site, Saint-Charles-Borromée

08003

GSK Investigational Site, Barcelona

08540

GSK Investigational Site, Centelles (Barcelona)

03600

GSK Investigational Site, Elda

08430

GSK Investigational Site, La Roca Del Valles (Barcelona)

PO6 3LY

GSK Investigational Site, Portsmouth

BD9 6RJ

GSK Investigational Site, Bradford

DD1 9SY

GSK Investigational Site, Dundee

EH16 4SA

GSK Investigational Site, Edinburgh

NE7 7DN

GSK Investigational Site, High Heaton, Newcastle Upon Tyne

SO16 6YD

GSK Investigational Site, Southampton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY